Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Acadia Surges as Parkinson’s Treatment Shows Benefit

Acadia Pharmaceuticals Inc. more than doubled in the shares’ biggest one-day increase ever after the company’s experimental treatment helped Parkinson’s disease patients with psychosis in a study.

Acadia rose to $5.43 at the close of New York trading, its largest jump since the stock began trading in May 2004. The shares have quadrupled in the past 12 months.

The drug, pimavanserin, met the primary goal of reducing psychotic symptoms in the late-stage study, the San Diego-based company said today in a statement. The most common side effects were urinary tract infections and falls, Acadia said.

Psychosis, which can include hallucinations and delusions, is common in patients with the advanced stages of Parkinson’s disease and there are no approved treatments for the condition, Acadia said. Pimavanserin is Acadia’s most advanced treatment in testing and would be the company’s first product on the market if approved.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.